Skip to content
Clinical Trials – home

Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello

Verified siteinfo

Italy Via Trabucco 180, 90146 Palermo, Italy

  • 34 trials recruiting
  • Acute myeloid leukaemia · Colitis ulcerative · Diffuse large B-cell lymphoma
  • Adults and children

About Specializations

Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello in Palermo, Italy specialises in clinical trials of conditions such as Acute myeloid leukaemia, Colitis ulcerative, Diffuse large B-cell lymphoma, Chronic lymphocytic leukaemia, and other specialisations. This site conducts important research.

Main research areas of the site

Hematology and Oncology

The medical center is at the forefront of hematology and oncology, with a particular focus on Acute Myeloid Leukemia (AML) carrying the FLT3 mutation. The institution is dedicated to advancing personalized treatment strategies that enhance patient outcomes.

  • Acute Myeloid Leukemia (AML) with FLT3 mutation
  • Peripheral Blast Clearance (PBC) as a biomarker
  • Customized therapy approaches

Through innovative research, the center is pioneering the use of the PBC biomarker to tailor therapies, aiming to improve event-free survival (EFS) in patients with low chemosensitivity. This involves early intensification of treatment during both the induction and consolidation phases, including high-dose delivery and allocation to allogeneic transplant, compared to standard regimens.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Via Trabucco 18090146 PalermoItaly
Recruiting now
34 trials
Conditions studied
63
Partner status
Verified site

More sites in PalermoItaly

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

103 clinical trials

Crohn's disease

Recruiting

Study of tulisokibart compared to placebo in adults with moderate to severe Crohn's disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Tulisokibart
  • Sponsor:Merck Sharp & Dohme LLC

Long‑Term Safety Study of ADX‑324 in Participants with Hereditary Angioedema (Phase 3 Extension)

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:ADX-324
  • Sponsor:Adarx Pharmaceuticals Inc.
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anumigilimab
  • Sponsor:CSL Behring LLC

Study of glofitamab, obinutuzumab and tocilizumab in patients with mantle cell lymphoma relapsed or refractory after CAR‑T therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Glofitamab
  • Sponsor:Fondazione Italiana Linfomi Ets

A study to evaluate the effectiveness of pirtobrutinib in elderly and frail patients with mantle cell lymphoma who have not yet received treatment.

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:65+ years
  • Substances:Pirtobrutinib
  • Sponsor:Fondazione Italiana Linfomi Ets

A study of bleximenib combined with intensive chemotherapy for adults with newly diagnosed acute myeloid leukemia with specific genetic changes.

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bleximenib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

A Study of Maribavir for Cytomegalovirus Infection in Stem Cell Transplant Patients Who Cannot Take or Did Not Tolerate Standard Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Maribavir
  • Sponsor:Gruppo Italiano Per Il Trapianto Di Midollo Osseo Cellule Staminali Emopoietiche E Terapia Cellulare

A Study of ADX-324 to Prevent Attacks in Patients With Hereditary Angioedema

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:ADX-324
  • Sponsor:Adarx Pharmaceuticals Inc.

Study comparing daratumumab, lenalidomide and dexamethasone followed by linvoseltamab versus continued initial treatment in newly diagnosed multiple myeloma patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Study of rilzabrutinib tablets compared to placebo in adults with warm autoimmune hemolytic anemia

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Rilzabrutinib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study Comparing Single and Dual Antiplatelet Therapy with Clopidogrel and Acetylsalicylic Acid in Elderly Patients or Those at Risk of Bleeding After Balloon Surgery

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Fondazione Ricerca e Innovazione Cardiovascolare

Study on Rilzabrutinib for Patients Aged 10-65 with Sickle Cell Disease

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Rilzabrutinib
  • Sponsor:Sanofi-Aventis Recherche & Developpement
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.